Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Chairman, CEO and Interim CFO Quang X. Pham recently disposed of 11,156 shares of the company's common stock, realizing a total proceeds of $33,919. The divestment was executed over a two-day period, with share prices fluctuating between $3.00 and $3.18. According to a Form 4 filing, Mr. Pham sold 2,127 shares on June 25, 2026, at $3.00 per share. On the following day, June 26, 2026, he sold an additional 9,029 shares at a weighted average price of $3.05 per share. These transactions were facilitated under a Rule 10b5-1 trading arrangement, which Mr. Pham established on September 25, 2025.
The insider activity follows a period of price weakness for the biotech firm. The stock has declined approximately 13% over the past week and is currently trading near its 52-week low of $2.55. Despite the recent price action, InvestingPro analysis suggests the stock may be undervalued relative to its Fair Value estimate. The platform categorizes CVKD among stocks with potential upside on its Most Undervalued list, alongside other insights available to subscribers.
Following the direct sales, Mr. Pham retains a direct ownership stake of 105,989 shares of Cadrenal Therapeutics common stock. Furthermore, he holds an indirect interest in 200,000 shares through The PVBQ Living Trust. As the Trustee of this entity, Mr. Pham possesses sole voting and dispositive power, with his child designated as the sole beneficiary.
On the corporate development front, Cadrenal Therapeutics reported a net loss of $3.0 million for the fourth quarter ended December 31, 2025. This figure represents an improvement from the $4.2 million loss incurred during the same period in 2024. The company has also received guidance from the U.S. Food and Drug Administration for a pivotal Phase 3 trial of its drug candidate CAD-1005, which is intended for the treatment of heparin-induced thrombocytopenia. This guidance follows an End-of-Phase 2 meeting with the FDA, where the agency provided insights on protocol design and other trial specifics.
Additionally, Cadrenal plans to submit a Rare Pediatric Disease Designation request for tecarfarin to treat pediatric patients with Kawasaki disease. The company also announced that clinical data on CAD-1005 will be presented at the 34th Congress of the International Society on Thrombosis and Haemostasis in Paris. This presentation will cover results from a Phase 2 trial of CAD-1005. Cadrenal is preparing to advance to a randomized, blinded, placebo-controlled Phase 3 study for CAD-1005, which is expected to enroll approximately 120 patients globally.
CVKD stock is currently trading at $3.05, reflecting a change of +0.1900 (+6.64%) from the previous close. The stock is closed at 15:59:59 USD. In after-hours trading, the price is recorded at 16:10:05 with a value of 3.0500, showing no change (0.00%).